Coston McIsaac & Partners grew its position in Pfizer Inc. (NYSE:PFE – Free Report) by 3.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,629 shares of the biopharmaceutical company’s stock after acquiring an additional 635 shares during the period. Coston McIsaac & Partners’ holdings in Pfizer were worth $719,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Legacy Trust lifted its position in shares of Pfizer by 6.6% during the 1st quarter. Legacy Trust now owns 16,012 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 993 shares in the last quarter. Moody National Bank Trust Division lifted its holdings in Pfizer by 0.4% during the first quarter. Moody National Bank Trust Division now owns 149,373 shares of the biopharmaceutical company’s stock valued at $6,094,000 after purchasing an additional 543 shares in the last quarter. Seelaus Asset Management LLC grew its position in shares of Pfizer by 201.7% in the first quarter. Seelaus Asset Management LLC now owns 21,809 shares of the biopharmaceutical company’s stock valued at $884,000 after purchasing an additional 14,580 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Pfizer by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 364,900 shares of the biopharmaceutical company’s stock worth $14,888,000 after purchasing an additional 2,200 shares in the last quarter. Finally, SOL Capital Management CO raised its position in shares of Pfizer by 24.1% during the 1st quarter. SOL Capital Management CO now owns 54,214 shares of the biopharmaceutical company’s stock worth $2,212,000 after purchasing an additional 10,538 shares during the last quarter. 67.80% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms have commented on PFE. Credit Suisse Group lowered Pfizer from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $47.00 to $40.00 in a research note on Thursday. Morgan Stanley reduced their price objective on Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pfizer in a report on Wednesday, May 17th. Daiwa Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target on the stock. in a research note on Thursday, May 11th. Finally, UBS Group lowered their price target on shares of Pfizer from $41.00 to $39.00 in a research report on Friday, May 5th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $46.67.
Insider Transactions at Pfizer
Pfizer Price Performance
PFE stock opened at $36.68 on Monday. Pfizer Inc. has a 52-week low of $35.76 and a 52-week high of $54.93. The business has a fifty day moving average of $38.32 and a two-hundred day moving average of $42.05. The stock has a market cap of $207.07 billion, a price-to-earnings ratio of 7.22, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31.
Pfizer (NYSE:PFE – Free Report) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.23. The firm had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. Pfizer’s revenue was down 28.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.62 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 4.47%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is 32.28%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
